Given the availability of longitudinal data for PD APOE4 carriers and non-carriers from baseline to 1-,2-, and 4- year follow ups under consistent inclusion and exclusion criteria of the present study, these current findings may provide a basis for analysis aimed at tracking APOE4’s effect on gray matter changes and its associations with cognitive trajectories overtime. Here, APOE is linked to Parkinson disease.